Intervention Review

You have free access to this content

Quetiapine versus typical antipsychotic medications for schizophrenia

  1. Sirijit Suttajit1,*,
  2. Manit Srisurapanont1,
  3. Jun Xia2,
  4. Siritree Suttajit3,
  5. Benchalak Maneeton1,
  6. Narong Maneeton1

Editorial Group: Cochrane Schizophrenia Group

Published Online: 31 MAY 2013

DOI: 10.1002/14651858.CD007815.pub2


How to Cite

Suttajit S, Srisurapanont M, Xia J, Suttajit S, Maneeton B, Maneeton N. Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD007815. DOI: 10.1002/14651858.CD007815.pub2.

Author Information

  1. 1

    Chiang Mai University, Department of Psychiatry, Faculty of Medicine, Chiang Mai, Thailand

  2. 2

    The University of Nottingham, Cochrane Schizophrenia Group, Nottingham, UK

  3. 3

    Chiang Mai University, Faculty of Pharmacy, Chiang Mai, Thailand

*Sirijit Suttajit, Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand. sirijits@gmail.com. ssuttaji@mail.med.cmu.ac.th.

Publication History

  1. Publication Status: New
  2. Published Online: 31 MAY 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
vs CPZ - Ai 2007 {published data only}
  • Ai L. A comparative study of efficacy and safety of seroquel versus chlorpromazine in the treatment of schizophrenia. Heilongjiang Medical Journal 2007;31(4):285.
vs CPZ - AstraZeneca 2005 {unpublished data only}
  • AstraZeneca. A Multicenter, double-blind, randomized, comparison of quetiapine (SEROQUEL®) and chlorpromazine in the treatment of subjects with treatment-resistant schizophrenia. http://www.clinicalstudyresults.org/ 2005.
vs CPZ - Bai 2005 {published data only}
  • Bai Y, Jiang K, Wang L. A random chlorpromazine-controlled study of the effects of quetiapine on cognition in schizophrenia. Shanghai Archives of Psychiatry 2005;17(3):151-4.
vs CPZ - Cao 2005 {published data only}
  • Cao D, Xie SP, Chen QB, Yuan YG, Fang Q. Characteristics of the sexual disturbance caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids in male patients with schizophrenia. Chinese Journal of Clinical Rehabilitation [Zhongguo Lin Chuang Kang Fu] 2005;9(36):63-8.
vs CPZ - Chen 2001 {published data only}
  • Chen J, Zhao J, Li L. Multi-center, double blind control study of domestic manufactured quetiapine on schizophrenia. Chinese Journal of Psychiatry 2001;34(4):193-6.
  • Zhao JP, Chen JD, Chen YG, Shu L, Ma C. A double-blind and double-dummy comparative study of quetiapine and chlorpromazine in the treatment of schizophrenia. Chinese New Drugs Journal 2002;11(2):149-51.
vs CPZ - Chen 2007b {published data only}
  • Chen F, Chen Y, Zhou B, Cheng F, Liu Y, Zho XW, et al. Quetiapine treatment in schizophrenia curative effect and quality of life. Linchuang Jingshen Yixue Zazhi 2007;17(5):319-20.
vs CPZ - Guo 2003 {published data only}
  • Guo BY, Wang YB. Control studies on efficacy of quetiapine vs chlorpromazine in first - episode schizophrenics. Journal of Clinical Psychosomatic Diseases 2003;9(2):75-7.
vs CPZ - Guo 2007 {published data only}
  • Guo J, Cao C, Wu D. Effect of quetiapine and chlorpromazine on cognitive function in first-episode schizophrenic. Chinese Journal of Health Psychology 2007;15(7):583-4.
vs CPZ - He 2003 {published data only}
  • He YD, Zhao CM, Shao AL, Chen YN. A comparative study of quetiapine and chlorpromazine in the treatment of patients with schizophrenia. Herald of Medicine 2003;22(10):680-2.
vs CPZ - Hu 2003 {published data only}
  • Hu JM, Li Yi, Li Tao, Wang HM, Liu XH, Huo KJ. The effects of antipsychotics on serum prolactin in the first-episode schizophrenia patients. West China Journal of Pharmaceutical Sciences 2003;18(6):467-9.
vs CPZ - Ji 2004 {published data only}
  • Ji J, Ou W. Comparative study between the quality of life and its curative effect in schizophrenic patients treated with quetiapine or chlorpromazine. Sichuan Mental Health 2004;17(2):73-5.
vs CPZ - Jiang 2006 {published data only}
  • Jiang KD, Bai YL, Peng DH, Tang MQ, Fan JX, Ma JS. A random and controlled study of quetiapine and chlorpromazine in patients with schizophrenia. Linchuang Jingshen Yixue Zazhi 2006;16(6):352-3.
vs CPZ - Jin 2007 {published data only}
  • Jin S, Liu S, Sang W, Zhao M. Seroquel and chlorpromazine in treatment of schizophrenia: a random, controlled trial. China Pharmaceuticals 2007;16(19):56-7.
vs CPZ - Li 2003 {published data only}
  • Li M, Hu F, Wang S. A study of quetiapine and chlorpromazine on the effects and quality of life in the treatment of schizophrenia. Shandong Archives of Psychiatry 2003;7488(3):135-7.
vs CPZ - Link 1997 {published data only}
vs CPZ - Mei 2007 {published data only}
  • Mei AC. Comparison of efficacy and safety of quetiapine and chlorpromazine in the treatment of schizophrenia. Medical Journal of Chinese People's Health 2007;19(17):723-4.
vs CPZ - Peng 2006 {published data only}
  • Peng ZG, Zhou JX, Kuang WH, Li J, Huang MS. A randomized double - blind controlled study on the efficacy of quetiapine and chlorpromazine in treatment of schizophrenia. West China Journal of Pharmaceutical Sciences 2006;21(6):606-8.
vs CPZ - Tian 2006 {published data only}
  • Tian H, He Q, Du L, Wu R, Hui S, Zheng Q, et al. Comparative study on the effect of seroquel and chlorpromazine on schizophrenia. China Pharmacy 2006;17(9):682-3.
vs CPZ - Wang 2004 {published data only}
  • Wang XL, Jiang F, Li T. Comparison of efficacy and safety of quetiapine and larctigal in the treatment of schizophrenia. Chinese Journal of Behavioral Medical Science 2004;13(3):288-90.
vs CPZ - Wang 2005 {published data only}
  • Wang H, Peng D, Bai Y. Efficacy of quetiapine in the treatment of female patients with schizophrenia. Shanghai Archives of Psychiatry 2005;17(2):83-6.
vs CPZ - Zhang 2002 {published data only}
  • Zhang S, Li Y, Xu J. A double-blind study of domestic quetiapine and chlorpromazine in the treatment of schizophrenia. Shandong Archives of Psychiatry 2002;15(3):149-51. [EMBASE: 2006303274; MEDLINE: 16797162]
vs CPZ - Zhang 2003 {published data only}
  • Zhang HY, Wang X, Liu C, Shu L, Li H, Gu N, et al. A comparison study on efficacy and safety of quetiapine and chlorpromazine in the treatment of schizophrenia. Chinese Journal of Clinical Pharmacology 2003;19(3):163-6.
vs CPZ - Zhong 2005 {published data only}
  • Zhong CL, Cui YH. Comparative study of influence of quetiapine on life quality in schizophrenic patients. Journal of Clinical Psychological Medicine 2005;15(2):103-5.
vs CPZ - Zhou 2003 {published data only}
  • Zhou J, Li J, Kuang W. Comparison between quetiapine and chlorpromazine in cognitive function of schizophrenic patients. Chinese Mental Health Journal 2003;17(10):699, 700-1.
vs CPZ - Zhou 2004 {published data only}
  • Zhou SB, Sun XD, Li YM. A comparative study on quetiapine and chlorpromazine in the treatment of schizophrenia. Medical Journal of Chinese Peoples Health 2004;16(11):657-9.
vs CPZ - Zou 2006 {published data only}
  • Zou X, Zhou Y, Zhang W. Study on quetiapine and chlorpromazine in treatment of schizophrenia. China Pharmaceuticals 2006;15(12):51-2.
vs FLUPHEN - Conley 2005 {published data only}
  • Conely RR, Kelly DL, Nelson MW, Richardson CM, Feldman S, Benham R, et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clinical Neuropharmacology 2005;28(4):163-8.
vs HLP - Arvanitis 1997 {published data only}
  • Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group. Multiple fixed doses of "seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biological Psychiatry 1997;42:233-46.
vs HLP - Atmaca 2002 {published data only}
vs HLP - Copolov 2000 {published data only}
  • Copolov DL, Link CGG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychological Medicine 2000;30:95-105.
vs HLP - Emsley 1999 {published data only}
  • Emsley RA, Raniwalla J, Bailey PJ, Jones AM, on behalf of the PRIZE Study Group. A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated partial response to conventional antipsychotic treatment. International Clinical Psychophramacology 2000;15:121-31.
vs HLP - Emsley 2004 {published data only}
  • Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Journal of Clinical Psychiatry 2004;65:696-701.
vs HLP - Fl'hacker 2005 {published data only}
  • Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (EUFEST). American Journal of Psychiatry 2009;166:675-82.
  • Fleischhacker WW, Keet IPM, Kahn RS and EUFEST Steering Committee. The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial. Schizophrenia Research 2005;78(2-3):147-56.
  • Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, et al for the EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-97.
vs HLP - Huang 2007 {published data only}
  • Huang J, Xue S, Ye R. Comparison of compliance and effectiveness of quetiapine and haloperidol in the treatment of schizophrenia. International Medicine and Health Guidance News 2007;13(16):96-9.
vs HLP - McCue 2006 {published data only}
  • McCue RE, Waheed R, Urcuyo L, Orendain G, Joseph MD, Charles R, et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. British Journal of Psychiatry 2006;189:433-40.
vs HLP - Murasaki 1999 {published data only}
  • Murasaki M, Koyama T, Yamauchi T, Yagi MG, Ushijima S, Kamijima K. Clinical evaluation of quetiapine in schizophrenia - efficacy and tolerability of quetiapine compared with haloperidol in patients with schizophrenia. Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany. Hamburg, Germany, 1999.
vs HLP - Purdon 2001 {published data only}
  • Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with schizophrenia after treatment with quetiapine or haloperidol. Journal of Psychiatry & Neuroscience 2001;26:137-49.
vs HLP - Taneli 2003 {published data only}
  • Taneli B, Alptekin K, Bilici M, Birsoz S, Eker E, Cosar B, et al. Comparison of efficacy and tolerability of quetiapine and haloperidol in acute exacerbation of chronic or subchronic schizophrenia. Proceedings of the 16th European College of Neuropsychopharmacology Congress; 2003 Sep 20-24; Prague, Czech Republic. Prague, Czech Republic, 2003.
vs HLP - Velligan 2002 {published data only}
  • Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, et al. Does cognitive function improve with quetiapine in comparison to haloperidol?. Schizophrenia Research 2002;53:239-48.
vs HLP - Zou 2007 {published data only}
  • Zou JH, Zhou Y, Li XL. A clinical analysis between quetiapine and haloperidol in the treatment of schizophrenia. Medical Journal of Chinese People's Health 2007;19(11):434-5, 7.
vs PERPHEN - Chen 2007a {published data only}
  • Chen H, Liu JH. Controlled observation on senile schizophrenics treated with quetiapine and perphenazine. Linchuang Jingshen Yixue Zazhi 2007;17(5):321-2.
vs PERPHEN - L'rman 2005 {published data only}
  • Keefe RSE, Cilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al for the CATIE investigators and the neurocognitive working group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Archives of General Psychiatry 2007;64:633-47.
  • Lieberman JA, Stroup S, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209–23.
  • Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, et al for the CATIE investigators. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: Findings from the NIMH CATIE study. American Journal of Psychiatry 2007;164:428-36.
vs PERPHEN - Yi 2006 {published data only}
  • Yi QM, Fan WL, Chen ZQ. The contrast investigation between quetiapine and perphenazlne in the treatment of first episode of schizophrenia in children. Journal of the North Sichuan Medical College 2006;2(6):522-4.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Buckley 2001 {published data only}
  • Buckley PF. Comparison of the effects of quetiapine and haloperidol in a cohort of patients with treatment resistant schizophrenia. Schizophrenia Research 2001;49(1,2):221.
Cheng 2003 {published data only}
  • Cheng XF. Control observation of quetiapine vs chlorpromazine in schizophrenia. Journal of Clinical Psychosomatic Diseases 2003;9(2):78-80.
Du 2004 {published data only}
  • Du QX, Yu CF, Zhong W. A clinical comparative analysis of quetiapine and chlorpromazine in treatment of schizophrenia. Medical Journal of Chinese Peoples Health 2004;16(7):398-9.
Glick 2005 {published data only}
  • Glick ID, Marder SR. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry 2005;66(5):638-41.
Goldstein 1999 {published data only}
  • Goldstein J, Emsley R, Raniwalla J, Bailey P, Jones M. Efficacy and tolerability of quetiapine compared with haloperidol in schizophrenic patients partially responsive to conventional antipsychotic treatment. Proceedings of the 39th Annual Meeting of the New Clinical Drug Evaluation Unit; 1999 Jun 1-4; Boca Raton, Florida, USA. Boca Raton, Florida, USA., 1999.
Grecu 2006 {published data only}
  • Grecu G, Grecu GM, Pop M. Clinical effectiveness of atypical vs typical antipsychotics in treatment of schizophrenia patients. Proceedings of the 19th European College of Neuropsychopharmacology Congress; 2006 Sep 16-20; Paris, France. Paris, France, 2006.
Guo 2006 {published data only}
  • Guo XF, Zhao JP, Chen JD, Zhang ZC. The effect of chlorpromazine and quetiapine on serum lipid and glucose. Journal of Clinical Psychological Medicine 2006;16(5):257-9.
Hammond 2001 {published data only}
  • Hammond R, Bustillo J, Lauriello J, Keith SJ, Nadiga D. Efficacy of quetiapine in antipsychotic naïve patients. Schizophrenia Research 2001;49(1,2):231.
Jones 2006 {published data only}
  • Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost Utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry 2006;63:1079-87.
Keleman 2006 {published data only}
  • Kelemen O, Nagy O, Máttyássy A, Kiss I, Janka Z, Kéri S. Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia?. European Neuropsychopharmacology 2006;16(Suppl 4):S430.
Kelly 2005 {published data only}
Kelly 2006 {published data only}
  • Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology 2006;31(3):340-6.
Kong 2003 {published data only}
  • Kong DL, Zhang SQ, Shu MQ. Effects of quetiapine and chlorpromazine on serum prolactin of schizophrenics. Journal of Clinical Psychosomatic Diseases 2003; Vol. 9, issue 4:200-1.
Lee 2001 {published data only}
  • Lee M, Meltzer HY. Quetiapine is significantly superior to haloperidol and placebo in improving mood in patients with schizophrenia. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany. Berlin, Germany, 2001.
Loza 2001 {published data only}
  • Loza B, Kucharska-Pietura K, Debowska G. Atypical versus typical antipsychotic treatment prognosis in first-episode paranoid schizophrenia based on WCST and dichotic listening scores. European Neuropsychopharmacology 2001;11(3):285.
Ma 2004 {published data only}
  • Ma ZW, Li MX, Shi YZ, Wang LH. Quetipine (35 patients) vs chlorpromazine (34 patients) in treatment of schizophrenia. Chinese Journal of New Drugs and Clinical Remedies 2004; Vol. 23, issue 5:273-5.
Nai 2007 {published data only}
  • Nai X, Hu X, Qiu S. Effect of quetiapine on cognition function of patients with first episode schizophrenia. Journal of Medical Forum 2007;28(2):38-9.
Qiu 2003 {published data only}
  • Qiu Y, Ma L. A comparative study between quetiapine and haloperidol on the life quality of the patients with schizophrenia. Shandong Archives of Psychiatry 2003;7489(3):138-40.
Reveley 2001 {unpublished data only}
  • Reveley M. Seroquel Outcome Study (SOS): a multicentre double-blind randomised trial to compare the effects of seroquel and chlorpromazine on treatment outcome of schizophrenic patients. National Research Register 2001.
Richardson 2005 {published data only}
  • Richardson CM, Kelly DL, Gold JM, McMahon R, Yu Y, Conley RR. Risperidone vs quetiapine vs fluphenazine in treatment - resistant schizophrenia: neuropsychological outcome. Schizophrenia Bulletin. 2005; Vol. 31:501-2.
Sharma 2002 {published data only}
  • Sharma T. A multi-centre, double-blind, randomised trial to compare the effects of "seroquel" and haloperidol in schizophrenic patients with a history of partial response to antipsychotic treatment. National Research Register 2001.
Zhang 2007 {published data only}
  • Zhang L. A comparative study of quetiapine and chlorpromazine in the treatment of schizophrenia. Modern Medicine Journal of China 2007;9(2):97-8.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Altman 1996
Andreasen 1989
  • Andreasen NC. Scale for the assessment of negative symptoms (SANS). British Journal of Psychiatry 1989;7:53-8.
APA 1994
  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th Edition. Washington DC: APA, 1994.
APA 2004
  • American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 2nd Edition. Arlington (VA): American Psychiatric Association, 2004.
Bland 1997
Boissel 1999
  • Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
Buchanan 2005
  • Buchanan RW, Carpenter WT. Concept of schizophrenia. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. Lippincott Wiliams & Wilkins, 2005.
Carpenter 1984
Carpenter 1994
Chouinard 1980
  • Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The extrapyramidal symptom rating scale. Canadian Journal of Neurological Sciences 1980;7:233.
Deeks 2000
  • Deeks JJ. Issues in the selection of a summary statistic for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. The Cochrane Collaboration, 2000.
Divine 1992
Donner 2002
Easterbrook 1991
Egger 1997
  • Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
Elbourne 2002
  • Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. [PUBMED: 11914310]
Geddes 2000
Goldstein 1993
Goldstein 1995
  • Goldstein JM. Preclinical tests that predict clozapine-like atypical antipsychotic actions. Critical Issues in the Treatment of Schizophrenia 1995;10:95-101.
Goldstein 2007
  • Goldstein JM, Cristoph G, Grimm S, Liu JW, Widzowski D, Brecher M. Unique mechanism of action for the antidepressant properties of the atypical antipsychotic quetiapine. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA. 2007.
Gulliford 1999
  • Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: Data from the health survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
Guy 1976
  • Guy U. ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health, 1976.
Heres 2006
  • Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry 2006;163:185-94.
Higgins 2003
Higgins 2008
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org 2008.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Kay 1986
  • Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. New York: Multi-Health Systems Inc, 1986.
Kerwin 1994
Komossa 2010
Leucht 2005a
Leucht 2005b
Leucht 2008
  • Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. http://www.nature.com/mp/journal/vaop/ncurrent/full/4002136a.html (accessed 08 January 2008):1-19. [DOI: 10.1038/sj.mp.4002136]
Liu-Seifert 2005
  • Liu-Seifert H. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Medicine 2005;3(21):1-10.
Macaskill 2001
Marshall 2000
  • Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
Migler 1993
Moher 2001
  • Moher D, Schulz KF, Altman D for the CONSORT group. The CONSORT statement:revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285(15):1987-91.
Overall 1962
Priebe 1999
Saller 1993
Schünemann 2008
  • Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
Simpson 1970
  • Simpson EN, Angus JWF. A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scandinavica Supplementum 1970;212:11-9.
Srisurapanont 2004
Thorpe 2009
  • Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ : Canadian Medical Association journal (Journal de l'Association Medicale Canadienne) 2009;180(10):E47-57. [PUBMED: 19372436]
Ukoumunne 1999
  • Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):3-92.
Ware 1992
Xia 2007
  • Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. The Leeds Outcomes Stakeholders Survey (LOSS) Study. Proceedings of the 15th Cochrane Colloquium; 2007 23-27 October; Sao Paulo. 2007.
Xia 2009
  • Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.